Sugi Predict

Sugi Predict / Compounds / SCHEMBL2810189

SCHEMBL2810189

SCHEMBL2810189

N#CCC(=O)NC1(C(=O)NCc2ccc(Nc3ccc(Cl)cc3C(F)(F)F)cn2)CC1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 2/20 0.37
▸ CNR2 P34972 4/20 0.36
▸ P2RX7 Q99572 1/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ AR P10275 3/20 0.34
▸ CTSK P43235 1/20 0.34
▸ TRPV1 Q8NER1 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ PAX8 Q06710 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ RORC P51449 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2809043 0.89 CNR2 (0.38) CNR2P2RX7RAB9ACYP1A2CYP2D6
SCHEMBL13128856 0.89 CNR2 (0.36) CTSLCNR2P2RX7RAB9ACYP1A2
SCHEMBL2809946 0.88 CNR2 (0.39) CNR2P2RX7RAB9ACYP1A2CYP2D6
SCHEMBL2807298 0.87 CNR2 (0.40) CTSLCNR2P2RX7RAB9ACYP1A2
SCHEMBL13159819 0.86 CNR2 (0.38) CNR2P2RX7RAB9ACYP1A2CYP2D6
SCHEMBL2813270 0.86 CNR2 (0.36) CTSLCNR2P2RX7RAB9ACYP1A2
SCHEMBL2807122 0.86 AR (0.37) CTSLCNR2P2RX7RAB9ACYP1A2
SCHEMBL19418576 0.85 CNR2 (0.39) CNR2P2RX7RAB9ACYP1A2CYP2D6
SCHEMBL14856464 0.84 CNR2 (0.35) CTSLCNR2P2RX7RAB9ACYP1A2
SCHEMBL2810010 0.84 RAB9A (0.39) CTSLCNR2P2RX7RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 — — US disclosed
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 — — US disclosed
EP-2401256-B1 Compounds as bradykinin B1 antagonists BOEHRINGER INGELHEIM INT (DE) 2013-04-17 — — EP disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 — — US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 — — US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 — — US disclosed
WO-2010097372-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131075-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 CTSL 1731/4885CNR2 882/4885P2RX7 30/4885
US-20100240669-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 CTSL 1731/4885CNR2 882/4885P2RX7 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.